Acacia Pharma Group plc Admission To Trading On Euronext Brussels
February 23 2021 - 1:00AM
UK Regulatory
TIDMACPH
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA,
JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO
DISTRIBUTE THIS ANNOUNCEMENT
PUBLICATION IN APPLICATION OF ARTICLE 15 OF THE BELGIAN TRANSPARENCY ACT
OF 2 MAY 2007
Acacia Pharma Group plc
Admission to Trading on Euronext Brussels
Cambridge, UK and Indianapolis, US -- 23 February 2021, 08:00 CET:
Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT:
ACPH), a commercial stage biopharmaceutical company focused on
developing and commercializing novel products to improve the care of
patients undergoing serious medical treatments such as surgery, invasive
procedures, or chemotherapy, announces that, further to the
announcements on 18 February 2021 and 19 February 2021 regarding a
placing of new ordinary shares in the Company (the "New Ordinary
Shares") by means of an accelerated bookbuild offering (the "Placing"),
10,000,000 New Ordinary Shares have been issued and admitted to trading
on the regulated market of Euronext Brussels.
The New Ordinary Shares issued pursuant to the Placing have the same
rights and benefits as, and rank pari passu in all respects with, the
existing Ordinary Shares.
Following issuance of the New Ordinary Shares, as per 23 February 2021,
the Company's total issued share capital amounts to GBP1,993,789.02,
represented by 99,689,451 ordinary shares with one voting right per
share. The Company does not hold any ordinary shares in treasury and has
not issued any other voting securities. Therefore, the total number of
voting rights in the Company is 99,689,451. This number represents the
denominator for purposes of notifications under transparency
regulations.
On the basis of this information, shareholders of the Company can verify
whether they are above or below one of the thresholds of 5%, 10%, 15%,
20% and so on, in multiples of five, of the total voting rights, and
whether there is therefore an obligation to disclose that they have
reached, exceeded or fallen below any such threshold in accordance with
the Belgian Transparency Act of 2 May 2007. Notifications of major
shareholdings must be sent by email to Acacia Pharma, for the attention
of Ali Elsley at AliElsley@acaciapharma.com, as well as to the Belgian
Financial Services and Markets Authority (FSMA), at trp.fin@fsma.be.
The Company has in total 2,437,960 outstanding options and 2,861,500
Restricted Stock Units, for the benefit of current and former staff and
the managers of the group, conferring entitlement to subscribe for a
maximum total of 5,299,460 new ordinary shares, each conferring one
voting right.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@citigatedewerogerson.com
---------------------------------- --------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
---------------------------------- --------------------------------------
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United
Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
marketed in the US for the management of postoperative nausea & vomiting
(PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centered in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
www.acaciapharma.com
Important Information
These materials are not for release, publication or distribution,
directly or indirectly, in whole or in part, into or within the United
States (including its territories and possessions, any State of the
United States and the District of Columbia). These materials are for
informational purposes only and do not constitute or form part of any
offer or solicitation to purchase or subscribe for securities in the
United States. The securities referred to herein have not been and will
not be registered under the United States Securities Act of 1933, as
amended (the "US Securities Act"), or under the securities laws of any
state or other jurisdiction of the United States. The securities
referred to herein may not be offered or sold in the United States
except pursuant to an exemption from the registration requirements of
the US Securities Act and in compliance with any applicable securities
laws of any state or other jurisdiction of the United States. There will
be no public offer of securities in the United States.
This press release (and the information contained herein) is not for
release, publication or distribution, directly or indirectly, in whole
or in part, into or within Australia, Canada, Japan or South Africa or
any other jurisdiction where to do so might constitute a violation of
the relevant laws or regulations of such jurisdiction.
The offer set out in this press release is only addressed to and is only
directed at persons in member states of the European Economic Area (the
"EEA") who are "qualified investors" within the meaning of Article 2 (e)
of Regulation (EU) 2017/1129. In the United Kingdom, this press release
is addressed solely to, and is directed solely at, persons who (i) have
professional experience in matters relating to investments falling
within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (ii) are persons
falling within Article 49(2)(a) to (e) of the Order and other persons to
whom it may lawfully be communicated (all such persons together being
referred to as "relevant persons"). These materials are addressed only
to, and directed only at, relevant persons and qualified investors and
must not be acted on or relied on (i) in the United Kingdom, by persons
who are not relevant persons or (ii) in any member state of the EEA, by
persons who are not qualified investors. Any investment or investment
activity to which these materials relate is available only to, and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire any securities referred to herein will be engaged in only with,
in the United Kingdom, relevant persons, and in any member state of the
EEA, qualified investors.
This press release does not constitute, or form part of, any offer or
any solicitation of an offer to subscribe for any shares or other
securities.
(END) Dow Jones Newswires
February 23, 2021 02:00 ET (07:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024